Regenxbio Inc (RGNX)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	334,971	365,838	378,809	389,202	415,976	436,639	465,424	446,877	518,826	410,164	437,387	498,638	531,197	386,950	329,082	338,233	345,032	360,228	359,492	303,884
Total current liabilities	US$ in thousands	130,272	127,346	117,893	112,334	130,434	123,548	114,556	119,937	130,472	106,771	91,554	83,961	81,447	63,613	40,203	31,789	33,676	31,345	24,661	21,390
Current ratio		2.57	2.87	3.21	3.46	3.19	3.53	4.06	3.73	3.98	3.84	4.78	5.94	6.52	6.08	8.19	10.64	10.25	11.49	14.58	14.21

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $334,971K ÷ $130,272K
= 2.57

The current ratio for Regenxbio Inc has exhibited fluctuations over the past eight quarters, ranging from a low of 2.57 in Q4 2023 to a high of 4.06 in Q2 2022. Generally, a current ratio above 2 indicates that the company is capable of covering its short-term liabilities with its current assets.

The downward trend observed in the current ratio from Q2 2022 to Q4 2023 suggests a potential decrease in liquidity and the company's ability to meet its short-term obligations. However, it is important to note that even the lowest current ratio of 2.57 in Q4 2023 is still above the generally accepted threshold of 2, indicating that the company is still in a relatively healthy financial position in terms of liquidity.

It would be beneficial for stakeholders to monitor this trend closely to ensure that the company maintains a comfortable level of liquidity to meet its short-term obligations effectively.